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Abstract Although the in£uence of selective cyclooxygenase
(COX)-2 inhibitors on the proliferation of colon adenocarcino-
ma cells have been the subject of much investigation, relatively
little research has compared the e¡ects of di¡erent COX-2 in-
hibitors. Celecoxib strongly suppressed the proliferation of
COX-2 expressing HT-29 cells at 10^40 WM. NS-398 and ni-
mesulide also inhibited cell proliferation, whereas rofecoxib,
meloxicam, and etodolac did not. Only celecoxib induced apo-
ptosis of HT-29 cells, as detected on the basis of DNA frag-
mentation, TUNEL positivity, and caspase-3/7 activation. DNA
fragmentation was also increasd in COX-2 non-expressing cell
lines (SW-480 and HCT-116) by exposure to celecoxib for 6^24
h. All six COX-2 inhibitors suppressed the production of pros-
taglandin E2 by HT-29 cells, suggesting that the pro-apoptotic
e¡ect of celecoxib was unrelated to inhibition of COX-2. Inac-
tivation of Akt might explain the di¡erential pro-apoptotic ef-
fect of these selective COX-2 inhibitors on colon adenocarcino-
ma cells.
: 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Epidemiological studies have shown that chronic intake of
aspirin is associated with a reduction in the incidence of co-
lorectal cancer [1,2]. In a clinical trial, celecoxib [3] was found
to reduce the number and size of polyps in patients with
familial adenomatous polyposis (FAP). The e¡ects of several
non-steroidal anti-in£ammatory drugs (NSAIDs) on tumor
growth have also been demonstrated in animal models of
FAP [4] and chemical colon carcinogenesis [5^8]. These ob-
servations suggest that NSAIDs have a potent chemopreven-
tive e¡ect on colon cancer.
NSAIDs have also been shown to exert anti-proliferative
and pro-apoptotic e¡ects on a variety of cell lines, particularly
colon cancer cell lines [9,10], suggesting a possible mechanism
for their chemopreventive action on the colon. Although cy-
clooxygenase (COX) is the molecular target of most NSAIDs
[11], not only COX-dependent mechanisms [12,13] but also
COX-independent [14^16] mechanisms have been reported
for the anti-proliferative and pro-apoptotic actions of these
drugs. Accordingly, the mechanisms by which NSAIDs inhibit
cell proliferation and induce apoptosis remain unclear.
Classic NSAIDs not only inhibit COX-2, but also inhibit
COX-1, resulting in the common side e¡ect of gastric muco-
sal damage. To reduce the gastrointestinal side e¡ects of
NSAIDs, selective COX-2 inhibitors were developed [17],
and the e¡ect of these selective inhibitors on the proliferation
and apoptosis of colon cancer cells has been the subject of
much investigation in recent years [12,15,16,18]. However,
almost all of these studies have involved the comparison of
a COX-2 inhibitor with non-selective NSAID (or else no
comparison at all), so relatively little is known about the
comparative e¡ects of di¡erent selective COX-2 inhibitors
on cell proliferation and apoptosis. To address this issue, we
investigated the e¡ects of six major COX-2 inhibitors [17,19]
(celecoxib, rofecoxib, NS-398, nimesulide, meloxicam and eto-
dolac) on the proliferation and apoptosis of colon adenocar-
cinoma cells.
2. Materials and methods
2.1. Materials
NS-398 and nimesulide were purchased from Cayman Chemical
(Ann Arbor, MI, USA). The caspase inhibitor N-acetyl-Asp-Glu-
Val-Asp-aldehyde (Ac-DEVD-CHO; Promega, Medison, WI, USA)
and epidermal growth factor (EGF; Sigma, St. Louis, MO, USA)
were purchased from the indicated companies. Celecoxib, meloxicam,
and etodolac were obtained from Pharmacia K.K. (Tokyo, Japan),
Nippon Boehringer Ingelheim (Hyogo, Japan), and Wyeth Lederle
Japan (Tokyo, Japan), respectively. Rofecoxib (International Patent
Publication WO95/00501) was synthesized as reported elsewhere [20].
These drugs were dissolved in dimethyl sulfoxide and the ¢nal con-
centration of the vehicle in all cultures was 0.1%.
2.2. Cell culture
Human colon adenocarcinoma cell lines (HT-29, SW-480 and HCT-
116) were obtained from the American type culture collection (Rock-
ville, MD, USA), and were grown in RPMI 1640 medium (Gibco,
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Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine
serum (FBS), 100 U/ml penicillin, and 100 Wg/ml streptomycin (Gib-
co) at 37‡C in an atmosphere of 5% CO2.
2.3. Cell proliferation assay
Proliferation of HT-29 cells was estimated from the incorporation
of 5-bromo-2P-deoxyuridine (BrdU). The cells (4U103 or 1U104/well)
were exposed to test drugs during culture in 96-well plates containing
RPMI 1640 medium with 1% (v/v) FBS at 37‡C in an atmosphere of
5% CO2. After 24 or 96 h, BrdU (10 WM) was added to the medium,
and then the cells were incubated for another 16^18 h. Next, the cells
were ¢xed and BrdU incorporation was determined with a cell pro-
liferation enzyme-linked immunosorbent assay (ELISA) kit (Roche
Diagnostics, Mannheim, Germany) according to the manufacturer’s
instructions.
2.4. DNA fragmentation assay
Colon carcinoma cells (2U104/well) were treated with the test drugs
during culture for 6 or 24 h in 96-well plates containing RPMI 1640
medium with 1% (v/v) FBS at 37‡C in an atmosphere of 5% CO2.
Cytoplasmic DNA fragments, which are an indicator of apoptosis,
were measured with a DNA cell death detection ELISAPLUS kit
(Roche Diagnostics) according to the manufacturer’s instructions.
2.5. Terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling assay
HT-29 cells (6U104/well) were treated with the test drugs during
culture in 8-well chamber slides (IWAKI, Chiba, Japan) containing in
RPMI 1640 medium with 1% (v/v) FBS at 37‡C in an atmosphere of
5% CO2. After 24 h, the cells were ¢xed with 4% (w/v) neutral bu¡-
ered formalin for 10 min at room temperature, and then apoptotic
cells were identi¢ed by the terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) assay using an apoptosis
in situ detection kit (Wako, Osaka, Japan) according to the manufac-
turer’s instructions. The cells were counterstained with methyl green
(Wako).
2.6. Assay of caspase activity
HT-29 cells (2U104/well) were treated with the test drugs during
incubation in 96-well plates containing RPMI 1640 medium with 1%
(v/v) FBS at 37‡C in an atmosphere of 5% CO2. After 6 h, the level of
caspase activity in the cells was measured by an Apo-ONE1 homo-
geneous caspase-3/7 assay (Promega) according to the manufacturer’s
instructions.
2.7. Assay of PGE2 production
HT-29 cells (5U105/well) were pretreated with the test drugs during
incubation in 24-well plates containing RPMI 1640 medium with 1%
(v/v) FBS at 37‡C in an atmosphere of 5% CO2. After 1 h, calcium
ionophore A23187 (0.5 WM; Sigma) was added to the medium, and
the cells were incubated for another 30 min. Then the PGE2 level in
the culture medium was measured using a commercial ELISA kit
(Cayman) according to the manufacturer’s instructions.
2.8. Western blotting
Colon carcinoma cells were lysed in solubilization bu¡er (10 mM
Tris^HCl, pH 7.4, 1% (w/v) NP-40, 0.1% (w/v) sodium deoxycholate,
0.1% (w/v) sodium dodecyl sulfate, 0.15 M NaCl, 1 mM EDTA, and
10 Wg/ml aprotinin), and then centrifuged at 12 500Ug for 30 min to
remove cell debris. Subsequently, the supernatant was concentrated by
the precipitation of proteins with trichloroacetic acid at a ¢nal con-
centration of 3.3% (w/v). The resultant precipitate (50, 100, or 150 Wg)
was subjected to SDS^polyacrylamide gel electrophoresis using 10^
12.5% (w/v) acrylamide slab gels under reducing conditions. The sep-
arated proteins were electrotransferred to Immobilon1 polyvinylidene
di£uoride membranes (Millipore, Bedford, MA, USA). Then each
membrane was reacted with rabbit anti-Akt antiserum (New England
Biolabs, Beverly, MA, USA), rabbit anti-phospho-Akt antiserum
(Ser473) (Sigma), or rabbit anti-Bcl-2 polyclonal antiserum (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), followed by incubation
with alkaline phosphatase-conjugated anti-rabbit IgG (Sigma). Immu-
noreactive Akt, phospho-Akt, or Bcl-2 was visualized indirectly using
5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium as
the substrates.
3. Results
3.1. E¡ect of COX-2 inhibitors on the proliferation of HT-29
cells
Initially, we examined the e¡ect of six selective COX-2 in-
hibitors on the proliferation of HT-29 cells by measuring in-
corporation of BrdU to assess DNA synthesis (Fig. 1). HT-29
cells were incubated with each of the inhibitors for 24 h.
Celecoxib strongly suppressed cell proliferation in a concen-
tration-dependent manner and its IC50 value was 32.5 WM.
The most pronounced inhibitory e¡ect of celecoxib was ob-
served at 40 WM, with the growth of HT-29 cells being com-
pletely suppressed. Although NS-398 and nimesulide were less
e¡ective than celecoxib, these agents also inhibited the prolif-
eration of HT-29 cells. In contrast, rofecoxib, meloxicam, and
etodolac had no e¡ect on cell proliferation at concentrations
up to 100 WM. Prolonged exposure to rofecoxib, meloxicam,
or etodolac for 96 h also had no appreciable e¡ect on cell
proliferation.
Fig. 1. E¡ect of various COX-2 inhibitors on the proliferation of
HT-29 cells. The cells were treated with celecoxib (b), rofecoxib
(a), NS-398 (F), nimesulide (E), meloxicam (R), or etodolac (O)
for 24 h or 96 h. Cell proliferation was estimated from the incorpo-
ration of BrdU and is presented as a percentage of the control val-
ue. Data are the meanRS.D. of triplicate cultures and representa-
tive results from three independent experiments are shown.
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3.2. E¡ect of COX-2 inhibitors on apoptosis of colon carcinoma
cells
To determine whether suppression of HT-29 cell prolifera-
tion by COX-2 inhibitors was due to the induction of apopto-
sis, the appearance of DNA fragmentation (a hallmark of
apoptosis) after incubation with each inhibitor was quantita-
tively analyzed by an ELISA that speci¢cally detected cyto-
plasmic histone-associated DNA fragments, mononucleo-
somes, and oligonucleosomes. As shown in Fig. 2A, DNA
fragmentation was detectable after 6 h of incubation with
celecoxib at more than 40 WM. After 24 h, DNA fragmenta-
tion was increased. Following exposure to celecoxib at 100
WM, DNA fragments were released into the culture medium,
indicating that the cells had undergone secondary necrosis,
which usually occurs after apoptosis (Fig. 2B). In contrast,
NS-398 or nimesulide (which also inhibited cell proliferation)
and rofecoxib, meloxicam, or etodolac (which had no e¡ect
on proliferation) did not in£uence DNA fragmentation at
concentrations up to 100 WM after incubation for 6 or 24 h.
We also examined the e¡ect of the selective COX-2 inhibitors
on DNA fragmentation in two COX-2 non-expressing cell
lines, SW-480 [16] and HCT-116 [12]. As shown in Fig.
2C,D, the e¡ect of each COX-2 inhibitor on DNA fragmen-
tation in these cells was very similar to the e¡ect in HT-29
cells.
To con¢rm the pro-apoptotic e¡ect of incubation with
COX-2 inhibitors, the TUNEL assay was used. As shown in
Fig. 3, untreated HT-29 cells were not stained by the TUNEL
method. In contrast, after incubation for 24 h in the presence
of 40 WM celecoxib, 44% of HT-29 cells were TUNEL-pos-
itive, indicating the occurrence of apoptosis, whereas cells
treated with the other COX-2 inhibitors (100 WM) showed
no staining.
3.3. E¡ect of COX-2 inhibitors on caspase-3/7 activation in
HT-29 cells
Caspases are responsible for many of the biochemical and
morphological changes that occur during apoptosis, so we
investigated whether selective COX-2 inhibitors induced the
activation of caspase-3 and/or caspase-7 (caspase-3/7) in HT-
29 cells. As shown in Fig. 4, incubation of HT-29 cells for 6 h
with 40 WM celecoxib induced the activation of caspase-3/7,
while activation was completely blocked by incubation with
the caspase inhibitor Ac-DEVD-CHO. In contrast, the other
selective COX-2 inhibitors (100 WM) did not alter the basal
level of caspase-3/7 activity in HT-29 cells.
Fig. 2. E¡ect of various COX-2 inhibitors on DNA fragmentation in colon carcinoma cells. HT-29 cells were treated with celecoxib (b), rofe-
coxib (a), NS-398 (F), nimesulide (E), meloxicam (R), or etodolac (O) for 6 h (A) or 24 h (B). SW480 cells (C) or HCT116 cells (D) were
treated with celecoxib (b), rofecoxib (a), NS-398 (F), nimesulide (E), meloxicam (R), or etodolac (O) for 24 h. Then the level of DNA frag-
ments in the cytoplasm was measured by ELISA. The fold induction of DNA fragmentation is shown relative to the value for the control cul-
ture. Data are the meanRS.D. of triplicate cultures and representative results from three independent experiments are shown.
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3.4. E¡ect of selective COX-2 inhibitors on PGE2 production
by HT-29 cells
To examine the e¡ect of COX-2 inhibitors on PGE2 pro-
duction by HT-29 cells, the cells were treated with COX-2
inhibitors for 1 h and then stimulated with A23187. As shown
in Fig. 5, all of the COX-2 inhibitors suppressed PGE2 pro-
duction in a concentration-dependent manner over the range
from 0.001 to 0.1 WM.
3.5. E¡ect of COX-2 inhibitors on Akt activation in colon
carcinoma cells
Since serine/threonine kinase Akt (protein kinase B) is a
regulator of cell survival and apoptosis and its activation
has been shown to protect a variety of cells against apoptosis
[21], we examined the e¡ect of the six selective COX-2 inhib-
itors on Akt activation in two colon carcinoma cell lines. The
total amount of phosphorylated Akt was measured after 24 h
of incubation with COX-2 inhibitors using an anti-phospho-
Akt (Ser473) antibody, because activation of Akt occurs after
phosphorylation. As shown in Fig. 6A, 40 WM celecoxib de-
creased the level of phospho-Akt in HT-29 cells, while rofe-
coxib did not. When HT-29 cells (Fig. 6B) or SW-480 cells
(Fig. 6C) were incubated with 40 WM celecoxib and then
stimulated with EGF, suppression of Akt phosphorylation
in response to EGF was observed. In contrast, these e¡ects
were not seen with other selective COX-2 inhibitors.
In addition, we examined the e¡ect of the six selective
COX-2 inhibitors on the expression of Bcl-2, which is linked
to inhibition of apoptosis, in HT-29 cells. Western blotting
(Fig. 7) showed that Bcl-2 was expressed by HT-29 cells,
and little change was seen after treatment with any of the
COX-2 inhibitors.
Fig. 3. Detection of apoptotic HT-29 cells by the TUNEL assay. HT-29 cells were cultured without agents (a), or else were incubated with 40
WM celecoxib (b), 100 WM rofecoxib (c), 100 WM NS-398 (d), 100 WM nimesulide (e), 100 WM meloxicam (f), or 100 WM etodolac (g) for 24 h,
and then apoptotic cells were identi¢ed by the TUNEL assay. The cells were counterstained with methyl green. TUNEL-positive cells (apopto-
tic cells) are stained brown (magni¢cation: U50).
FEBS 26685 23-10-02
R. Yamazaki et al./FEBS Letters 531 (2002) 278^284 281
4. Discussion
In this study, we evaluated the e¡ects of six major selective
COX-2 inhibitors (celecoxib, rofecoxib, NS-398, nimesulide,
meloxicam and etodolac) on the proliferation and apoptosis
of colon adenocarcinoma cells. We clearly showed that cele-
coxib could strongly suppress cell proliferation. Although NS-
398 and nimesulide also inhibited the proliferation of HT-29
cells at higher concentrations, rofecoxib, meloxicam and eto-
dolac had no e¡ect. Among these six COX-2 inhibitors, only
celecoxib induced the characteristic features of apoptosis, in-
cluding DNA fragmentation, TUNEL-positivity and caspase-
3/7 activation, in colon carcinoma cells (HT-29, SW-480 and
HCT-116 cells). It has been reported that NS-398 also induces
apoptosis of colon carcinoma cells in vitro [15,18]. In the
present study, however, no such pro-apoptotic e¡ect was ob-
served, although NS-398 did inhibit cell proliferation. This
discrepancy may be explained by di¡erences of the culture
conditions. In previous studies, apoptosis was determined
after a relatively long culture period (4 days) when compared
with our study (6^24 h). The pro-apoptotic e¡ect of NS-398
on colon carcinoma cells may have been more apparent after
4 days of treatment. In contrast, we found that celecoxib
induced apoptosis after only 6 h. Taken together, these results
indicate that the pro-apoptotic mechanism of celecoxib may
be di¡erent from that of other selective COX-2 inhibitors.
HT-29 cells have served as a useful model for examining the
mechanisms by which NSAIDs reduce the proliferation of
colon cancer cells [9,10,14,15]. HT-29 cells express both
COX-1 and COX-2 proteins and mRNAs [14]. Although all
six selective COX-2 inhibitors that we tested shared the ability
to inhibit PGE2 production by HT-29 cells, these compounds
showed di¡erential suppression of cell proliferation and in-
duction of apoptosis. In addition, much higher doses of the
three active agents (celecoxib, NS-398 and nimesulide) were
required to achieve inhibition of cell growth than to inhibit
PGE2 production. Moreover, the di¡erential e¡ects of the
COX-2 inhibitors on DNA fragmentation in COX-2 non-ex-
pressing cell lines (SW-480 [16] cells and HCT-116 [12] cells)
were very similar to the e¡ects of these agents on HT-29 cells.
These results indicate that inhibition of COX-2 was not asso-
ciated with the anti-proliferative and pro-apoptotic e¡ects of
these COX-2 inhibitors on colon carcinoma cells. However,
there seems to be little doubt that COX-2 contributes to tu-
morigenesis in the colon, because all six COX-2 inhibitors that
we tested (celecoxib [6], rofecoxib [4], NS-398 [7], nimesulide
[5], meloxicam [22] and etodolac [8]) show an anti-tumor e¡ect
in animal models such as chemical colon carcinogenesis. These
¢ndings, combined with the present observations, suggest that
inhibition of cell proliferation and induction of apoptosis do
not fully explain the mechanism by which selective COX-2
inhibitors exert anti-tumor activity in vivo. It is possible
that indirect mechanisms, such as an anti-angiogenetic action
[23,24], may be more important than the direct e¡ects of such
agents on colon cancer cells in vivo.
It is also possible that some selective COX-2 inhibitors in-
duce apoptosis of colon carcinoma cells via targets that are
not necessarily related to COX-2 inhibitory activity. In this
respect, the observation that some NSAIDs act as a direct
ligand for peroxisome proliferator-activated receptor Q (PPARQ)
is of interest [25]. We recently found that various NSAIDs,
such as indomethacin, diclofenac, oxaprozin and zaltoprofen,
induced the apoptosis of rheumatoid synovial ¢broblasts in
association with PPARQ activation [26]. Furthermore, recent
studies have indicated that PPARQ is expressed by colon can-
cer cells, including HT-29 cells [27,28], and a selective PPARQ
ligand (troglitazone) causes growth inhibition and induces ap-
optosis in HT-29 cells [28]. However, we found that celecoxib
and NS-398 did not induce transcriptional activation of PPARQ
Fig. 4. E¡ect of various COX-2 inhibitors on caspase-3/7 activation
in HT-29 cells. The cells were cultured without agents (bar 1), or
else were incubated with 40 WM celecoxib (2), 40 WM celecoxib+10
WM Ac-DEVD-CHO (3), 100 WM rofecoxib (4), 100 WM NS-398
(5), 100 WM nimesulide (6), 100 WM meloxicam (7), or 100 WM eto-
dolac (8) for 6 h, and then caspase activity was measured by the
Apo-ONE1 homogeneous caspase-3/7 assay (Promega). The fold
changes of caspase activity are shown relative to the value for the
control culture. Data are the meanRS.D. of triplicate cultures and
representative results from two independent experiments are shown.
Fig. 5. E¡ect of various COX-2 inhibitors on PGE2 production by HT-29 cells. The cells were preincubated with the test drugs for 1 h at
37‡C, and then 0.5 WM calcium ionophore A23187 was added. After incubation for another 30 min, the PGE2 level in the culture medium was
measured by enzyme immunoassay. Data are the meanRS.D. of triplicate cultures. The PGE2 level in the control culture was 1.40R 0.08 ng/
ml. Representative results of three independent experiments are shown.
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in a luciferase reporter assay using a peroxisome proliferator
response element-driven luciferase reporter plasmid (data not
shown).
The serine/threonine kinase Akt (protein kinase B) is a reg-
ulator of cell survival and apoptosis, and its activation has
been shown to protect a variety of cells against apoptosis [21].
Recently, celecoxib was reported to induce apoptosis by
blocking the activation of anti-apoptotic Akt in prostate can-
cer cells via an action that was independent of Bcl-2 [29].
Since the optimum concentration of celecoxib and the incu-
bation time for induction of apoptosis in colon carcinoma
cells in the present study were similar to those reported for
prostate cancer cells, the e¡ect of celecoxib on colon carcino-
ma cells may also involve inhibition of Akt activation. In our
study, only celecoxib among six selective COX-2 inhibitors
decreased the level of phospho-Akt in HT-29 cells and SW-
480 cells by suppressing its phosphorylation. This mechanism
may explain the unique pro-apoptotic activity of celecoxib
and the di¡erential pro-apoptotic e¡ects of various selective
COX-2 inhibitors on colon carcinoma cells.
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